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Thyrotropin-releasing hormone (TRH), a neuromodulator and possibly a neurotransmitter in the central nervous
system, was shown in a prior study of young normal volunteers to attenuate the memory impairment induced
by the anticholinergic drug scopolamine. In the present study, the cognitive, behavioral and physiologic effects
of high dose TRH (0.5 mg/kg), both alone and following administration of scopolamine, were examined in 10
Alzheimer’s disease (AD) patients (mean age&plusmn;SD=63.5 years) and 12 older normal volunteers (mean
age=64.9&plusmn;8.8 years). On the day AD subjects received TRH alone, modest but statistically significant
improvement from baseline performance was documented on some tests of learning and memory, especially
in those with mild dementia severity. In comparing cognitive test performance between the scopolamine alone
and scopolamine+TRH conditions, only two test scores were significantly higher in the latter condition. In
the group of older volunteers, TRH did not attenuate scopolamine-induced cognitive impairment, contrary
to prior findings in a group of younger controls. In fact, older subjects performed worse after receiving
scopolamine followed by TRH than after receiving scopolamine alone. In addition, no change from baseline
cognitive performance was detected after subjects received TRH alone. These findings raise several questions
and speculations on possible age-related changes in the cholinergic system, as well as on the mechanism of
the interaction of TRH with the cholinergic system.
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Introduction
The tripeptide thyrotropin-releasing hormone (TRH) has
been proposed to have potential therapeutic value in
Alzheimer’s disease (AD) (Yarbrough, 1979; Metcalf,
1982). This proposal arises from the fact that TRH and
TRH analogs have been shown, in animal studies, to have
positive neuromodulatory effects on the cholinergic
system (Breese et al., 1975; Yarbrough, 1979; Horita,
Carino and Lai, 1986; Suzuki et al., 1989; Hutson,
Semark and Middlemeiss, 1990; Okada, 1991) and to
facilitate memory and learning in animal paradigms used
to model the memory impairment of AD [e.g. after
administration of the centrally active anticholinergic drug
scopolamine (Yamazaki, Nagaoka and Nagawa, 1986;
Yamamura et al., 1991) or lesions of the septo-
hippocampal system (Horita et al., 1989; Yamamura et
al., 1991)]. In addition, areas of the brain thought to
be involved in learning and memory, the amygdala,
hippocampus and temporal cortex, have high concentra-
tions of TRH receptors (Manaker et al., 1986). It has been
questioned, though, whether sufficient quantities of a
peptide such as TRH could be delivered across the blood-
brain barrier to the brain (Metcalf, 1982).
In a previous study, we administered intravenously high
doses of TRH (0.5 mg/kg) to young normal volunteers
and were able to demonstrate an attenuation of some of
the cognitive impairment induced by the anticholinergic
drug scopolamine (Molchan et al., 1990). The scopolamine
model of geriatric memory dysfunction is widely
employed experimentally (Drachman and Leavitt, 1974;
Bartus et al., 1982; Sunderland et al., 1986), and some
pharmacological agents that reverse scopolamine-induced
cognitive impairment have been shown to be of modest
benefit to memory performance of elderly subjects as well
as of some patients with AD (Drachman, 1977; Sitaram,
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Weingartner and Gillin, 1978; Mewaldt and Ghoneim,
1979; Mohs et al., 1985).
Given our previous experience with TRH in young
normals (Molchan et al., 1990), and two prior studies in
AD subjects using lower doses of TRH (Mellow et al.,
1989; Lampe et al., 1990), we sought to examine the
cognitive, behavioral and physiologic effects of high dose
TRH in a group of patients with AD and in older normal
volunteers. In addition, we hoped to learn about the
modulatory effects of TRH on responses to scopolamine
in these subject groups.
Methods
Subjects
Ten AD patients (four females and six males; mean
age + SD = 63.5 + 7.8 years) and 12 normal volunteers
(three females and nine males; mean age + SD = 64.9 ± 8.8
years) participated in the study after informed consent
and screening which excluded any medical or psychiatric
illness (Table 1). Probable AD was diagnosed according
to ADRDA/NINCDS criteria (McKhann et al., 1984).
Dementia severity was assessed by staff members during
the inpatient admission in which they participated in the
protocol, using the Global Deterioration Scale (GDS)
(Reisberg et al., 1982). All subjects were drug-free for
at least 3 weeks prior to the study. Normal volunteers
were paid for their participation.
Experimental design
After the baseline cognitive battery, subjects participated
in three study days, each separated by at least 72 h. On
each study day, beginning at about 8:30 a.m. an indwelling
i.v, catheter was inserted and scopolamine hydrobromide
(0.25 mg for AD patients and 0.5 mg for normals) or
placebo was administered, followed by either high dose
TRH (0.5 mg/kg) or placebo 45 min later. Drugs and
placebos were administered in a double-blind, randomized
manner. Cognitive testing was done on each study day
45 min after administration of TRH/placebo, i.e. 90 min
after scopolamine/placebo administration. Prior studies
Table 1 Clinical characteristics of older normal volunteers and
Alzheimer’s patients
Numbers are mean+SD.
dWechsler Memory Scale. bGlobal Deterioration Scale.
in humans have shown that the cognitive effects of i.v.
scopolamine peak from 90 to 150 min after
administration (Safer and Allen, 1971), and that central
effects of high-dose TRH occur between 30 and 90 min
after infusion (Mellow et al., 1989; Molchan et al., 1990).
Behavioral ratings and digit span testing were
performed by the physician investigator at four time
points on each study day, prior to, and 30, 60 and
135 min after scopolamine/placebo administration.
Behavioral ratings included two visual analog scales
(VAS), which range from 0 to 100 mm, and the NIMH
behavioral rating scale (which ranges from 0 or ’not
present’ to 6 or ’very marked’) and symptom checklist
(which ranges from 0 or ’none’ to 3 or ’much’) (van
Kammen and Murphy, 1975). An automated vital signs
monitor (Critikon Inc., Tampa, FL) recorded blood
pressure (BP) and heart rate, and oral temperature was
recorded on each study day 15 min and just prior to
administration of scopolamine or placebo (time 0), and
30, 45, 60, 90 and 135 min thereafter.
To obtain central cognitive effects, we administered a
very high dose of TRH since it crosses the blood-brain
barrier poorly (Metcalf, 1982), and is quickly
metabolized, having a plasma half-life of only 4-5 min
(Bassiri and Utiger, 1973). The dose of TRH was chosen
based on results from previous studies in which cognitive
effects were demonstrated using similar doses (Mellow
et al., 1989; Molchan et al., 1990). In addition, signific-
antly elevated levels of CSF TRH have been documented
120 min after peripheral administration of high doses of
the peptide (Mitsumoto et al., 1986). TRH was purchased
from Peninsula Laboratories (Belmont, CA) and
analyzed for purity by the NIH Pharmaceutical
Development Service.
The dose of scopolamine used in the AD group was
chosen based on results from a prior study which showed
that after 0.25 mg, side effects are tolerable such that
cognitive testing can usually be completed, with a
significant decline in cognitive performance demonstrated
(Sunderland et al., 1987). In the normal volunteers, the
dose was chosen based on a prior study of a range of
scopolamine doses which showed that statistically
significant decreases in cognitive test performance in older
normal volunteers occur at the 0.5 mg dose (Sunderland
et al., 1987).
Note that no placebo/placebo day was included in the
study design, which was established primarily to compare
performance among drug conditions. No statistically
significant differences between performance on similar
cognitive test batteries administered at baseline, prior to
a subject’s participation in drug studies, and cognitive
performance during placebo conditions had been shown
in 14 young normal volunteers (Sitaram, Weingartner and
Gillin, 1978) and 11 AD patients (Tariot et al., 1987) by
ANOVA. Retrospective analysis of variance (ANOVA)
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of data from another study, of 10 AD patients and 10
older controls, also showed no differences between
baseline and placebo day cognitive performance. These
data were collected in conjunction with a study examining
the effects of a range of scopolamine doses in those
subjects (Sunderland et al., 1987); it was not included in
that report but the data are available on request. In
addition, no differences have been shown between tests
of memory and information processing done prior to drug
administration (time 0) and after administration of
placebo (Wesnes and Warburton, 1984; Sunderland et al.,
1987). For these reasons the cognitive test results from
the baseline day were included in some statistical analyses
as noted below. In addition, it seemed that the advantage
of having a true placebo day would be negligible in that
prior studies have shown that the side effects of
scopolamine and TRH are such that the blindness of
placebo versus scopolamine or TRH conditions would
be compromised (Sunderland et al., 1987; Mellow
et al., 1989).
Cognitive tests
Subjects were administered a baseline cognitive battery
that included the Wechsler Memory Scale (WMS)
(Wechsler, 1945) and tests of attention, memory and
learning. Tests were administered in the same order on
each study day, beginning with the vigilance task,
followed by category retrieval and then the selective
reminding test. For the normal volunteer group, a
continuous performance task (CPT) was administered at
the end of the test session. Digit span was tested four
times during each study day, in conjunction with
behavioral ratings. Descriptions of the tests have been
published previously (Sunderland et al., 1987) and are
summarized below.
Vigilance task
Subjects were read a list of 12 categorically related
words, six of which were repeated; subjects were
instructed to signal the examiner upon hearing a word
for the second time as a measure of vigilance-attention.
The number of correctly identified words that had been
heard twice (a maximum of six words) was recorded as
the score. Subjects were later asked to freely recall items
from the list. Subjects were then read a list of 24 words,
12 of which were from a previously presented list (where
six had been presented once and six had been presented
twice), and 12 completely new words. Accuracy of the
recognition of words that had been presented previously
(either once or twice) was recorded as a measure of
recognition memory. As words were recognized, subjects
were asked to recall how frequently a word had been
presented (once or twice). The difference between the
mean reported frequency of the once-presented and twice-
presented words was used as a measure of automatic
memory processes (Hasher and Zacks, 1979).
Category retrieval
As a measure of retrieval from knowledge memory,
subjects were given two letters and asked to generate
words beginning with those letters. They were then given
words representing a broad category and asked to
generate related words (Battig and Montague, 1969).
Responses were recorded over a 90 s period.
Selective reminding test
As a test of episodic learning and memory, subjects were
read a list of six categorically unrelated words and were
asked to recall them; missed words were repeated by the
examiner and recall was attempted again. This process
was repeated for a total of eight trials. A free recall
score and a consistency of recall score were recorded
(Buschke, 1973).
Continuous performance task
As a measure of choice reaction time, a CPT was
administered to the group of normal volunteers. During
the approximately 8 min of this test, subjects were
instructed to attend to a screen on which 1, 3 or 6 letters
appeared, for a period of 1, 3 or 6 s, respectively.
Following this exposure, a single letter appeared, and
subjects were instructed to press a button labeled ’yes’
if the letter had been displayed previously, or a button
labeled ’no’ if it had not. The times between stimulus
presentation and correct response for each trial were
averaged to obtain the mean reaction time; accuracy was
recorded as the percentage of correct responses.
Digit span
Subjects were read random sequences of digits and were
asked to recall them immediately, in either the sequence




Cognitive data from the three drug conditions were
analyzed by one-way repeated measures ANOVA
accompanied by a priori contrasts between the
scopolamine and scopolamine + TRH conditions. In all
analyses, the data met the assumption of homogeneity
of covariance; therefore corrections for lack of
homogeneity were not applied. The ANOVA was also
carried out with the baseline condition included, as noted
above in the explanation of the experimental design, with
accompanying a priori contrasts between baseline and
scopolamine alone, scopolamine and scopolamine + TRH,
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and baseline and TRH alone. One-tailed probabilities
were used with the analysis of the AD data, based on the
hypothesis that TRH would improve cognitive function
and on evidence from prior studies that it does so,
including two studies of AD patients (Yamazaki,
Nagaoka and Nagowa, 1986; Horita et al., 1989; Mellow
et al., 1989; Lampe et al., 1990; Molchan et al., 1990).
Two-tailed probabilities were used for the normal
volunteer data. A binomial (signed rank) test was also
performed to compare cognitive test scores after
scopolamine and after scopolamine + TRH in the normals.
ANOVA was also used to check for carry-over or order
effects of drug administration.
Behavioral data from the VAS were analyzed using
repeated measures ANOVA to evaluate both of the
within-subject variables of drug condition and time
simultaneously, with a priori contrasts between study
days. One-tailed probabilities were used to maximize
detection of the described analeptic effect of TRH (Breese
et al., 1975; Horita, Carino and Lai, 1986; Mellow et al.,
1989) on measures of alertness, concentration and
drowsiness. The maximum change from baseline values
Table 2
Scores presented as mean+SD. SCOP = scopolamine. Numbers in parentheses include the range of test scores.
§p < 0.05, ~/?< 0.005, for companson between baseline and scopolamme conditions.
*p < 0.05, tp < 0.1, for comparison between scopolamine and scopolamine + TRH conditions.
**p < 0.05, ~p< 0. I , for comparison between baseline and TRH conditions. I
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(max delta) for each variable on each study day was
evaluated for statistical significance using paired t-tests.
Max deltas between the scopolamine and scopolamine +
TRH conditions and the scopolamine + TRH and TRH
conditions were compared using repeated measures
ANOVA accompanied by a priori contrasts. Possible
relationships between cognitive test scores and the VAS
behavioral measures of alertness and drowsiness that were
recorded just prior to cognitive testing were examined using
Pearson’s product-moment correlations (Winer, 1982).
Physiologic data were analyzed using one-way repeated
measures ANOVA, and paired t-tests (two-tailed) to
detect significant changes from baseline measures within
each drug condition. The maximum increase in each
parameter for each drug condition was compared using
repeated measures ANOVA accompanied by a priori
contrasts between the scopolamine and scopolamine +




Mean scores for each of the tests under the various study
conditions are summarized in Table 2a. A significant
decrease from baseline performance on several cognitive
tests occurred after subjects received scopolamine alone,
consistent with findings from prior studies (Sunderland
et al., 1987). During the scopolamine + TRH condition,
recognition of twice-presented words and backward digit
span were better as compared with scopolamine alone;
[F(1,9)=3.8, p<0.05] ] and [F(1,9)=5.6, p<0.02],
respectively (Table 2a); other test scores were unchanged.
Results for the comparison between the scopolamine and
scopolamine + TRH conditions were the same whether the
results from the baseline day were included in the
ANOVA or not. Cognitive performance improved
significantly from baseline after TRH on the selective
reminding task and at a trend level of significance on the
estimation of word frequency, used as a measure of
automatic processing (Table 2a).
For the subjects with the highest WMS scores, and
whose dementia severity was mild to moderate, as rated
by the GDS, performance improved on more tests, and
to a greater degree, than performance in the overall group
after TRH administration. Test scores for which
improvement was demonstrated in this subgroup are
depicted in Fig. 1 and included: selective reminding test
free recall [F(1,3) = 4.3, p < 0.05 ] , selective reminding
test recall consistency [F(1,3) =10.3, p < 0.03 ] , automatic
processing [F(1,3) = 5.5, p<0.05] ] and free recall of
twice-presented words [F(1,3) = 6.0, p < 0.05 ] .
No significant correlations were found between
performance on the selective reminding test and the VAS
Figure 1 Cognitive test scores (mean + SE) are represented for
the four AD subjects with the highest WMS scores, comparing
individual cognitive tests at baseline with scores after high
dose TRH administration. Tests depicted in the graph, from
left to right, are selective reminding test free recall (Recall),
selective reminding test consistency (CN), a measure of
automatic processing (Freq), free recall of once-presented
words (FR1) and free recall of twice-presented words (FR2).
*p < 0.05
behavioral measures of alertness and drowsiness in the
overall group of subjects. Significantly, there were no
carry-over effects, or effects of the order of drug
administration as detected by ANOVA.
Normal subjects
Table 2b summarizes the mean scores for each of the
cognitive tests under the various study conditions. As
expected, cognitive performance declined significantly
after administration of scopolamine alone, with either
no change or further decline on some tests after
scopolamine + TRH. After administration of TRH alone,
a significant decline in score was measured on the word
category retrieval test and on recognition of words that
had been presented once (Table 2b). Drug-induced
alterations in test scores were consistent for the individual
subjects, i.e. there were no outliers. In addition, no carry-
over or order effects were detected. No test score
increased during the scopolamine + TRH as compared
with the scopolamine alone condition. Scores were
significantly lower during the scopolamine + TRH
condition as compared with scopolamine alone (p < 0.001 )
using the binomial test. No significant correlations were
found between selective reminding test scores and
behavioral measures of alertness and drowsiness.
To examine whether age may have affected cognitive
testing or drug response, the group was divided into those
< 65 (n = 5) and those > 65 (n = 7), and t-tests were used
to compare cognitive tests scores during each of the drug
conditions between these two subgroups. Baseline scores
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Figure 2 Cognitive test scores (mean + SE) during the
scopolamine + TRH condition for which a significant
difference was found between normal volunteers > 65 and
<65 years old. Tests depicted are as in Fig. 1, with the
addition of a total free recall score (Free R) from the vigilance
task, and letter fluency score (Letters). *p < 0.05
and scores after scopolamine alone did not differ
significantly between the two subgroups. The older
subjects’ scores were lower than the relatively younger
subjects’ on most of the tests during the scopolamine +
TRH condition. This difference was significant for
selective reminding free recall (t= -2.23, 10 d.f.,
p < 0.05), selective reminding consistency (t = - 2.24,
10 d.f., p<0.05), word frequency (t= -2.3, 10 d.f.,
p < 0.04), total free recall of the words from the vigilance
task (t= -2.9, 10 d.f., p<0.01), and letter fluency
(t= -3.1, 10 d.f., p<0.01) (Fig. 2).
Behavioral measures-Alzheimer’s patients
Results for VAS behavioral data comparing drug
conditions as analyzed by repeated measures ANOVA and
using max deltas were similar; the max delta data are
summarized in Table 3. No differences from baseline were
detected on the day subjects received TRH alone (Table 3).
Table 3 Comparison of maximum changes from baseline of behavioral effects
(as evaluated by visual analog scales) across baseline and three drug conditions
in Alzheimer’s patients (n = 10) and normal volunteers (n = 12)
Scores are expressed as mean + SD. SCOP = scopolamme.
§p < 0.05, ~~p < 0.001 for baseline compared with scopolamine.
*p < 0.05, **p < 0.001, for baseline compared with scopolamine + TRH.
tp < 0.02 different from scopolamine alone.
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None of the subjects became delusional or experienced
hallucinations during any of the study days. Besides those
included in Table 3, physical side effects, as evaluated
using VAS and the NIMH scale, included slightly blurred
vision in three patients after scopolamine, a shivering
response lasting about 10 min after TRH administration
in all, a brief urge to micturate in three patients after TRH
and one after scopolamine, and an unusual taste in three
patients after TRH administration.
Normal subjects
Behavioral data are summarized in Table 3; results were
similar to those of the AD group.
Physiological measures-Alzheimer’s patients
Physiologic data are represented graphically in Fig. 3. In
comparing the maximum increases from baseline values
among drug conditions, significant differences were
found between scopolamine and scopolamine + TRH for
systolic BP [F(1,9) = 5.8, p < 0.04], diastolic BP [F(1,9) =
6.3,p<0.03] ] and temperature [F(1,9) = 6.3, p < 0.04 ] .
The mean maximum increases from baseline in systolic
and diastolic BP, heart rate and temperature were
greater after administration of TRH alone as compared
with scopolamine + TRH, but the differences were not
statistically significant.
Normal subjects
Figure 3 summarizes the physiologic data. The only
measure showing a significant difference in maximum
increase from baseline between drug conditions was
systolic BP, in the comparison between scopolamine and
scopolamine + TRH [F(l,ll)=19.9,/?<0.001].
Discussion
In a prior study, we showed that TRH attenuated the
cognitive impairment associated with scopolamine
administration in young normal volunteers (Molchan et
al., 1990). Since the cognitive effects of scopolamine in
older normals have been compared to the cognitive profile
of AD patients, we expected that administration of TRH
may lead to improved cognitive performance in AD
subjects. However, after TRH administration to 10 AD
patients, mean scores improved significantly from
baseline only on the selective reminding test, a measure
of new learning and memory. The cognitive performance
of the four subjects with the highest WMS scores
improved to a greater degree and on a larger number of
cognitive tests than the overall group (Fig. 1), indicating
that the brains of these less impaired subjects were better
able to respond to the intervention than the more severely
demented patients.
TRH attenuated the cognitive effects of scopolamine
only on a recognition memory test and backward digit
span (Table 2a). In the prior study of young normal
volunteers, TRH attenuated the effects of scopolamine
on a larger number of tests (Molchan et al., 1990).
Presumably, this would be due to the inability of already
compromised cholinergic systems in the AD subjects to
recover from the additional anticholinergic, cognition-
impairing effects of scopolamine.
The effects of TRH in older normal volunteers were
somewhat anomalous, in that their cognitive performance
decreased after the addition of TRH to scopolamine, with
no change or a decrease from baseline scores after
administration of high dose TRH alone (Table 2b). This
differs from findings in young normal volunteers and
animal studies, in which TRH and TRH analogs attenuate
scopolamine-induced cognitive impairment (Yamazaki,
Nagaoka and Nagawa, 1986; Horita et al., 1989; Molchan
et al., 1990; Yamamura et al., 1991). In the comparison
of cognitive test results of those less than or equal to
65 and those over 65, several test scores during the
scopolamine + TRH condition (and not at baseline or the
other drug conditions) were significantly lower in those
over 65 as compared with the relatively younger group.
This decrease is different from results in the prior study
of young volunteers (Molchan et al., 1990) and cannot
be explained by baseline differences, as baseline cognitive
performance between the two groups was not significantly
different, as assessed by t-tests (unpublished data). The
cognitive findings in older volunteers also contrast with
those of AD patients, though results from the two groups
are not directly comparable as they received different
doses of scopolamine.
The contrasting findings between the previous study
in young normal volunteers (Molchan et al., 1990) and
the present results in older normals raise several questions
and speculations on possible differences in patho-
physiologic changes which occur in the cholinergic system
with age and in AD, as well as on the mechanisms of
interaction between TRH and the cholinergic system in
older, as compared with younger, subjects. The most
consistently demonstrated findings in the cholinergic
system that occur in the aged brain are decreased
acetylcholine (ACh) synthesis (Gibson, Peterson and
Jenden, 1981; Decker, 1987), decreased ACh release
(Decker, 1987; Wu et al., 1988) and decreased responsivity
of cholinergic neurons to ACh (Bartus et al., 1982; Lippa
et al., 1985; Decker, 1987). Theories as to the mechanism
by which TRH may interact with the cholinergic system
to improve cognitive performance in scopolamine-treated
young human subjects and animals, in animals with
septo-hippocampal lesions and in patients with AD
include: (1) an increase in the synthesis (Narumi et al.,
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1983) and/or release of ACh (Suzuki et al., 1989; Hutson,
Semark and Middlemeiss, 1990; Okada, 1991); (2) an
increase in ACh receptor sensitivity (Winokur and
Beckman, 1978) (though this has not been observed by
some investigators); and (3) direct excitation of cerebral
cortical (Lamour, Dutar and Jobert, 1983) and septo-
hippocampal neurons (Lamour et al., 1989). A direct
action of TRH at the cholinergic receptor has not been
demonstrated. In that TRH has been shown to facilitate
ACh release, and ACh availability and release may be
impaired with ageing (Decker, 1987; Wu et al., 1988), the
most likely explanation for the differential effects of
scopolamine + TRH in older and younger subjects may
be decreased release of ACh by TRH in the older subjects.
An additional change shown to occur with age in
several animal and human studies is that with increasing
age there is a loss of muscarinic receptors in the cerebral
cortex (White et al., 1977; Perry, 1980; Nordberg and
Winblad, 1981; Rinne, 1987; Pedigo, 1988; Schwarz et
al., 1990). Some animal studies have shown that this loss
is due primarily to a decrease in the density of type 1
muscarinic (M 1 ) receptors (Pedigo, 1988; Schwarz et al.,
1990). In contrast, in AD a decrease in the density of type
2 muscarinic (M2) receptors has been documented, with
that of M1 receptors remaining relatively intact (Mash,
Flynn and Potter, 1985; Araujo et al., 1988; Lange et
al., 1990).
Speculatively, our data may suggest that scopolamine,
which blocks M receptors with significantly higher
affinity than M2 receptors (Burke, 1986), may therefore
allow the autoregulatory pre-synaptic M2 receptors to
decrease ACh release, especially in older normals who
may have fewer M1 and relatively intact numbers of M2
receptors in the first place (Pedigo, 1988; Schwarz et al.,
1990). Possibly, because of this or other age-related
changes, the facilitatory effect of TRH on the cholinergic
system may not occur in normal older subjects as it
apparently did in younger subjects (Molchan et al., 1990).
Instead, a functionally inhibitory effect on cholinergic
transmission may occur. If TRH is acting in our paradigm
to increase the effects of ACh, this explanation may be
consistent with differential findings between age groups
in a recent animal study in which performance of old but
not young rats on a test of spatial reference memory
declined after acute treatment with an M cholinergic
agonist, though subsequently improved after more
chronic treatment (Brandeis et al., 1990).
It should also be noted that alterations in other
neurotransmitter systems that occur with age may impact
on cholinergic system responsivity and on memory
performance (Thompson et al., 1984; Zornetzer, 1986;
Marcyniuk, Mann and Yates, 1989; Wenk et al., 1989),
and that TRH affects some of these systems, most notably
the noradrenergic and dopaminergic (Metcalf, 1982;
Horita, Carino and Lai, 1986). We cannot rule out, and
acknowledge that it is likely, that neurotransmitter or
neuromodulator systems besides the cholinergic
contributed to the effects of TRH. If other systems such
as the noradrenergic are facilitated (Horita, Carino and
Lai, 1986), the rationale for the use of TRH for AD
patients is strengthened, in view of the documented
deficits in a number of neurotransmitter systems in this
disease (Price, 1986; Zweig et al., 1988).
The question of whether behavioral side effects may
have influenced cognitive test performance after the
administration of scopolamine and TRH recurs in every
study that utilizes these agents. TRH has analeptic effects
(Breese et al., 1975; Horita, Carino and Lai, 1986;
Mellow et al., 1989) which could conceivably contribute
to its attenuation of some of the effects of scopolamine,
which usually causes some drowsiness. The analeptic
effect does not seem to be a factor in the present study,
as shown by the lack of significant change on the measure
of vigilance-recognition, forward digit span and CPT in
the normals (Table 2b), which were used as measures of
attention, and the lack of significant correlations between
cognitive test scores and measures of drowsiness and
alertness on the day subjects received TRH. Moreover,
on the day subjects received TRH, there were no
differences from baseline in alertness, drowsiness and
other behavioral measures, nor were there significant
differences on these parameters between the scopolamine
and scopolamine + TRH conditions (Table 3). In addition,
in a recently completed study of young normal volunteers,
we found that the stimulant dextroamphetamine did not
attenuate the cognitive effects of scopolamine (Martinez
et al., in preparation).
It should be emphasized that, although high dose TRH
has side effects, such as the shivering response, these are
transient, so that, by the time of cognitive testing, the
blindness (as to whether TRH or placebo may have been
administered) of the person administering the cognitive
tests was not compromised. Also, subjects were
unaware of the cognitive response expected after TRH
administration.
The changes in systolic BP recorded in this study
(Fig. 3) were consistent with findings from prior studies
showing a marked pressor effect of TRH (Horita,
Figure 3 Effects of scopolamine alone, scopolamine + TRH, and TRH alone on blood pressure, heart rate, and temperature
in AD (upper four graphs) and normal subjects (lower four graphs) across time. *p < 0.05, * *p < 0.01 for comparisons with
baseline values within each study day. Scopolamine or placebo was administered at time 0, and TRH or placebo at time + 45.
-0- TRH, - - - - 0 .... Scop + TRH, -~ - Scop
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Carino and Lai, 1986; Mellow et al., 1989; Molchan et
al., 1990), the etiology of which has been posulated to
involve central muscarinic receptors (Horita, Carino and
Lai, 1986; Mattila and Bunag, 1986; Okuda, Mizobe and
Miyazaki, 1987; Brezenoff, Vargas and Xiao, 1988). The
mean increases in BP, both systolic and diastolic, were
highly variable, and greater on the day subjects received
TRH alone as compared with the day they received
scopolamine + TRH. These differences did not reach
statistical significance, with the exception of systolic BP
in the volunteers, which is consistent with cholinergic
system involvement in the pressor response induced by
TRH in that group. The observed increase in temperature
is consistent with studies showing a thermogenic effect
of TRH (Horita, Carino and Lai, 1986). The mean
temperature increase was greater on the day subjects
received TRH alone (Fig. 1) than on the day they received
scopolamine + TRH, though the difference was not
statistically significant.
In summary, high dose TRH modestly improved
cognitive performance in a subgroup of mildly impaired
patients with AD. This finding is consistent with those
of two prior studies which examined high dose TRH
(0.3 mg/kg i.v.) (Mellow et al., 1989) and high dose TRH
(up to 12 mg i.v.) in combination with lecithin (Lampe
et al., 1990). These results suggest that further studies
with TRH and TRH analogs, which are much more
biologically stable than the native peptide as well as more
accessible and specific to the central nervous system
(Griffiths et al., 1989), may be warranted in patients with
this illness. TRH analogs too, have been shown, in animal
studies, to facilitate impaired memory performance to a
greater degree than TRH itself (Yamazaki, Nagaoka and
Nagawa, 1986; Yamamura et al., 1991). Also, like many
peptides, TRH has been shown to exhibit trophic activity
in the nervous system (Faden, Jacobs and Smith, 1984;
Behbehani et al., 1990), and it has been hypothesized that
trophic factors may be of benefit to patients with AD
(Hefti, Dravid and Hartikka, 1984: Price, 1986).
Results in older volunteers in the present study were
contrary to findings in a group of young controls, in
whom an attenuation of scopolamine-induced cognitive
impairment occurred after TRH administration,
presumably by facilitating cholinergic system function
(Molchan et al., 1990). These contrasting results suggest
that the changes that occur in the brain with age, whether
in receptor density, receptor sensitivity, second messenger
systems or through some other mechanism, may change
the response to this neuropeptide. The cognitive and
physiologic responses reported in this study also differed
from those reported in age-matched AD subjects and
imply that some of the changes in neurochemical systems
and mechanisms involved in the cognitive impairment
which occur in normal ageing and in AD may be
different. This remains a topic of some controversy
(Whitehouse and Au, 1986; Decker, 1987). Pharmacologic
models similar to the one used in this study should be
useful for further investigations of the neuromodulatory
effects of peptides and the complex changes that occur
with ageing and disease.
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